SEC Form 4 · accession 0000899243-19-002323
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Patrick Shannon Jr.
Officer — See Remarks
Period of report
Jan 31, 2019
Accepted (ET)
Feb 1, 2019 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.88 | Jan 31, 2019 | A | 80,000 | A | — | Jan 31, 2029 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F125% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Remarks
Executive Vice President and Chief Operating Officer